Lawsuits allege that long-term Depo-Provera use can increase the risk of certain brain tumors (meningiomas) and that the manufacturer did not adequately warn users. This article covers the legal basis and what to expect.
Women who have used Depo-Provera, an injectable contraceptive medication, and later received a diagnosis of a brain tumor known as a meningioma may have legal options. Recent scientific research has identified a potential link between long-term use of Depo-Provera and the development of meningiomas, which are typically benign brain tumors that can cause serious symptoms and require treatment.
The Depo-Provera brain tumor lawsuit represents a developing area of pharmaceutical litigation where women are seeking compensation for injuries they believe were caused by the medication. If you've used Depo-Provera for an extended period and have been diagnosed with a meningioma, understanding your legal rights and options is important.
What Is Depo-Provera?
Depo-Provera is an injectable contraceptive medication that contains the hormone medroxyprogesterone acetate. The medication is administered as an injection every three months to prevent pregnancy. It has been used by millions of women worldwide since its approval by the FDA in 1992.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
The medication works by preventing ovulation and thickening cervical mucus to block sperm. While effective for birth control, emerging research has raised concerns about potential long-term health risks, particularly related to brain tumor development. Many women have used Depo-Provera for extended periods, sometimes for years or even decades, which may have contributed to the increased risk observed in recent studies.
Depo-Provera injections are typically administered by healthcare providers into the muscle of the arm or buttock. Each injection releases the hormone slowly over time, maintaining contraceptive effectiveness for approximately 12 to 14 weeks. The cumulative exposure from repeated injections over many years may be a factor in the increased meningioma risk observed in long-term users.
The Connection Between Depo-Provera and Brain Tumors
Women who developed meningiomas after Depo-Provera injections may qualify for compensation.
No-cost evaluation for women who used Depo-Provera and developed a brain tumor.
Check your Depo-Provera eligibilityScientific research has identified a potential link between progestogen-containing medications like Depo-Provera and the development of meningiomas. Meningiomas are tumors that form in the meninges, the protective membranes surrounding the brain and spinal cord. While most meningiomas are benign, they can grow large enough to cause significant symptoms and may require surgical removal.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
Studies have found that women who used progestogen-based contraceptives, including Depo-Provera, for extended periods may have an increased risk of developing meningiomas. The risk appears to be higher in women who used the medication for longer durations, suggesting a dose-response relationship. This means that the longer someone used Depo-Provera, the greater their potential risk.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
The mechanism by which progestogens may contribute to meningioma development is not fully understood, but research suggests that these hormones may stimulate the growth of meningioma cells. Meningiomas have been found to have receptors for progestogen hormones, which may explain why exposure to these hormones could promote tumor growth.
Who May Qualify for a Depo-Provera Lawsuit?
Women who may qualify for a Depo-Provera lawsuit typically share certain characteristics related to their medication use and medical diagnosis. Understanding these factors can help you determine whether you may have a valid claim.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Duration of Use: Women who used Depo-Provera for extended periods, particularly five years or more, may have a stronger case. The risk of meningioma development appears to increase with longer duration of use, so those who received injections over many years may be more likely to qualify.
A confidential case review can help you understand your Depo-Provera legal options.
No obligation. Understand your Depo-Provera legal options at no cost.
Request a free Depo-Provera evaluationThe National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Meningioma Diagnosis: A confirmed diagnosis of meningioma is typically required. This diagnosis is usually made through imaging studies such as MRI or CT scans, and may be confirmed through biopsy if surgery is performed. The diagnosis should have occurred after a period of Depo-Provera use.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Timing of Diagnosis: The timing between Depo-Provera use and meningioma diagnosis is important. While there's no specific time limit, cases where the diagnosis occurred during or after Depo-Provera use may be more relevant than cases where the diagnosis occurred many years before starting the medication.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
Medical Documentation: Having medical records that document both your Depo-Provera use history and your meningioma diagnosis is important. These records help establish the connection between the medication and your condition.
If you've used Depo-Provera and received a meningioma diagnosis, you may want to learn whether you qualify for a free case review. This initial evaluation can help determine whether your situation may meet the criteria for pursuing a legal claim.
Don't wait on your Depo-Provera claim—statutes of limitations may apply.
Get a free Depo-Provera case review and learn whether you may qualify.
See if you qualify for a Depo-Provera lawsuitCurrent Status of Depo-Provera Brain Tumor Litigation
Litigation related to Depo-Provera and meningiomas is developing as more women learn about the potential connection between their medication use and brain tumor diagnosis. Cases are being filed alleging that manufacturers knew about the risks but failed to adequately warn patients and healthcare providers.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
The litigation is in early stages, with cases being filed in various courts. As more scientific evidence emerges and more women come forward, the litigation may develop into consolidated proceedings similar to other pharmaceutical mass tort cases. Scientific evidence continues to accumulate linking progestogen exposure to meningioma development, and this evidence may support legal claims that manufacturers had an obligation to warn about these risks but failed to do so adequately.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Evidence suggests that the risks associated with progestogen exposure were known for years before adequate warnings were provided. Pharmaceutical companies have a legal obligation to warn patients and healthcare providers about known risks. If you've used Depo-Provera for an extended period and developed a meningioma, you may be entitled to compensation for medical expenses, lost wages, pain and suffering, future medical care, and reduced quality of life.
If you used Depo-Provera and were diagnosed with a brain tumor, you may have legal options.
Free, confidential Depo-Provera case review. Find out if you qualify.
Get a free Depo-Provera case reviewCommon Symptoms of Meningiomas
Meningiomas can cause a variety of symptoms depending on their size and location. Understanding these symptoms can help you recognize potential warning signs and seek appropriate medical care.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
Headaches: Persistent or worsening headaches are one of the most common symptoms of meningiomas. These headaches may be different from typical headaches and may worsen over time.
Vision Problems: Meningiomas located near the optic nerve or other visual pathways can cause vision changes, including blurred vision, double vision, or loss of vision in one or both eyes.
Seizures: Some meningiomas can cause seizures, particularly if they're located in areas of the brain that control motor function or consciousness.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Women who developed meningiomas after Depo-Provera injections may qualify for compensation.
No-cost evaluation for women who used Depo-Provera and developed a brain tumor.
Check your Depo-Provera eligibilityCognitive Changes: Meningiomas may cause changes in memory, concentration, or other cognitive functions, especially if they're large or located in areas that affect brain function.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Weakness or Numbness: Depending on the location of the tumor, meningiomas can cause weakness or numbness in various parts of the body.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Hearing Loss: Meningiomas located near the auditory nerve can cause hearing loss or ringing in the ears.
It's important to note that these symptoms can have many causes, and having these symptoms doesn't necessarily mean you have a meningioma. However, if you've used Depo-Provera and are experiencing any of these symptoms, it's important to discuss them with your healthcare provider and consider whether imaging studies may be appropriate.
What a Case Review Involves
A case review is an initial evaluation to determine whether you may have a valid legal claim related to Depo-Provera use and meningioma development. This process is confidential, free, and does not create any obligation on your part.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
A confidential case review can help you understand your Depo-Provera legal options.
No obligation. Understand your Depo-Provera legal options at no cost.
Request a free Depo-Provera evaluationThe National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Initial Consultation: The process typically begins with a conversation about your Depo-Provera use history and medical diagnosis. You'll be asked about when you started using Depo-Provera, how long you used it, when you received your meningioma diagnosis, and what symptoms you've experienced. This information helps determine whether your situation may qualify for a lawsuit.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Medical Records Review: If you decide to proceed, medical records related to your meningioma diagnosis and treatment may be reviewed. This helps establish the connection between your medication use and your condition. You may also be asked about your Depo-Provera injection history and any documentation you have.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
Eligibility Assessment: Based on the information gathered, an assessment will be made about whether you may qualify to pursue a claim. Factors considered include the duration of your Depo-Provera use, the timing of your diagnosis, and how your case fits within the broader litigation.
Next Steps: If you may qualify, you'll be informed about the next steps in the legal process. This might include connecting you with an independent law firm that handles Depo-Provera cases. If you don't qualify, you'll receive an explanation of why.
Don't wait on your Depo-Provera claim—statutes of limitations may apply.
Get a free Depo-Provera case review and learn whether you may qualify.
See if you qualify for a Depo-Provera lawsuitThe National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
No Upfront Costs: Case reviews are conducted at no cost to you. If you qualify and choose to proceed with a case, most attorneys work on a contingency fee basis, meaning they only receive payment if your case is successful. To understand more about how mass tort cases work, you may find our guide on understanding mass tort litigation helpful.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
The case review process is designed to be straightforward and respectful of your situation. The goal is to help you understand your options and determine whether pursuing legal action makes sense for your circumstances. If you're ready to begin, you can contact us for a free case review.
Practical limits on any lawsuit
Courts evaluate meningioma claims individually. Past settlements or news reports do not set your value; medical proof, duration of use, and defense arguments all matter in a confidential review.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
If you used Depo-Provera and were diagnosed with a brain tumor, you may have legal options.
Free, confidential Depo-Provera case review. Find out if you qualify.
Get a free Depo-Provera case reviewScientific Evidence: While research suggests a link between Depo-Provera and meningiomas, scientific evidence continues to evolve. Courts will evaluate this evidence, and outcomes may depend on how juries and judges interpret the available research.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
Litigation Timeline: Mass tort litigation typically takes several years to resolve. Cases may proceed through discovery, expert witness preparation, and potentially trials or settlement negotiations. The timeline for your specific case depends on many factors beyond your control.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
See if you qualify for a free case review to learn more about your potential rights and options. You can also learn more about Depo-Provera lawsuit information and your potential rights.
Frequently Asked Questions
- Q: What is a meningioma?
- A meningioma is a type of brain tumor that forms in the meninges, the protective membranes surrounding the brain and spinal cord. While most meningiomas are benign, they can grow large enough to cause symptoms and may require treatment, including surgery.
Women who developed meningiomas after Depo-Provera injections may qualify for compensation.
No-cost evaluation for women who used Depo-Provera and developed a brain tumor.
Check your Depo-Provera eligibilityThe National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
The National Brain Tumor Society notes that meningiomas account for roughly one-third of all primary brain tumors in adults—context that helps readers understand why even a modest relative risk increase can affect many patients.
- Q: How long do you have to use Depo-Provera to be at risk?
- Research suggests that longer duration of use is associated with increased risk. Women who used Depo-Provera for five years or more may have a higher risk, but the exact duration required varies. Each case is evaluated individually based on its specific circumstances.
- Q: What should I do if I've been diagnosed with a meningioma after using Depo-Provera?
- If you've been diagnosed with a meningioma after using Depo-Provera, you may want to consider a free case review to determine whether you may qualify for a lawsuit. It's also important to continue working with your healthcare providers to manage your condition and receive appropriate medical care.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
- Q: How much compensation might I receive?
- A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
Compensation amounts vary significantly based on individual circumstances, including the severity of your condition, medical expenses, lost wages, and other factors. Past results don't guarantee future outcomes, and each case is evaluated individually.
According to WHO classification data, meningiomas are typically graded WHO Grade I tumors, yet surgical resection rates climb when tumors enlarge or compress critical structures.
- Q: Do I need to have had surgery to qualify?
- Surgery is not necessarily required to qualify for a lawsuit. Cases are evaluated based on individual circumstances, including the size and location of the meningioma, symptoms experienced, and treatment received or recommended.
- Q: How long do Depo-Provera lawsuits take?
- Mass tort litigation typically takes several years to resolve. The timeline depends on many factors, including how the litigation develops, whether cases are consolidated, and whether settlements are reached. Your specific case timeline may vary.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
- Q: What if I used Depo-Provera many years ago?
- The timing of your Depo-Provera use and meningioma diagnosis is important, but there's no specific time limit that automatically disqualifies a case. Each situation is evaluated individually, and statutes of limitations vary by state.
Important Disclaimers
Understanding your legal options related to Depo-Provera brain tumor lawsuits is an important first step for women who have used the medication and been diagnosed with meningiomas. If you've used Depo-Provera for an extended period and have been diagnosed with a meningioma, understanding your legal rights and options is important.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
A 2024 *BMJ* study of French national health data reported that prolonged use of medroxyprogesterone acetate injectable contraception was associated with a 5.6-fold higher risk of intracranial meningioma requiring surgery among long-term users compared with non-users.
According to FDA approval history, Depo-Provera (medroxyprogesterone acetate injectable suspension) has been marketed in the United States since 1992, with labeling updated multiple times as progestin safety data evolved.
If you think a product, drug, or exposure harmed you, documenting your timeline early helps attorneys evaluate the claim. Request a free, confidential case review when you are ready.
Top Tier Legal, LLC is not a law firm and does not provide legal advice. This content is for informational purposes only. Submitting information does not create an attorney-client relationship. If you qualify, Top Tier Legal, LLC may connect you with an independent law firm. Past results do not guarantee future outcomes.
